Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Inozyme Pharma Inc.: Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function | 107 | GlobeNewswire (Europe) | - Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT - BOSTON, July 25... ► Artikel lesen | |
02.07. | Inozyme gets Fast Track status for candidate for rare calcification condition | 1 | Seeking Alpha | ||
02.07. | Inozyme's INZ-701 Receives FDA Fast Track Designation For ABCC6 Deficiency | 1 | RTTNews | ||
02.07. | Inozyme Pharma Inc.: Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency | 72 | GlobeNewswire (Europe) | BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for... ► Artikel lesen | |
30.06. | Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts? | 1 | Insider Monkey | ||
21.06. | Inozyme Pharma Inc.: Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH) | 1 | GlobeNewswire (USA) | ||
20.06. | Inozyme Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.05. | Inozyme Pharma Inc.: Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences | 1 | GlobeNewswire (USA) | ||
08.05. | Inozyme Pharma Inc.: Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference | 1 | GlobeNewswire (USA) | ||
08.05. | Inozyme Pharma GAAP EPS of -$0.38 beats by $0.02 | 1 | Seeking Alpha | ||
07.05. | Inozyme Pharma Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
07.05. | Inozyme Pharma Inc.: Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights | 141 | GlobeNewswire (Europe) | - Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase... ► Artikel lesen | |
07.05. | Inozyme Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
07.05. | Inozyme Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
03.05. | Inozyme Pharma Inc.: Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 82 | GlobeNewswire (Europe) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the... ► Artikel lesen | |
08.04. | Inozyme Reports Positive Topline Data From Phase 1/2 Study Of INZ-701; Stock Up | 3 | RTTNews | ||
08.04. | Inozyme Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.04. | Inozyme Pharma Inc.: Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency | 73 | GlobeNewswire (Europe) | - Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study... ► Artikel lesen | |
06.04. | Inozyme Pharma Inc.: Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 297 | GlobeNewswire (Europe) | BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the... ► Artikel lesen | |
02.04. | Inozyme Pharma Inc.: Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MEDIGENE | 1,135 | -1,30 % | PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/23.07.2024/11:15) - Die Medigene AG ( http://www.medigene.de... ► Artikel lesen | |
BB BIOTECH | 45,650 | +0,77 % | Ihre wichtigsten Termine: Spannende Q-Zahlen von: Mercedes-Benz, Hensoldt, BB Biotech, Wacker Chemie & 3M | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:00 Uhr, Schweiz:... ► Artikel lesen | |
QIAGEN | 40,195 | +2,62 % | Biotech Report: Qiagen knapp im Plus, Evotec geben ab | (shareribs.com) Frankfurt / New York 23.07.2024 - Biotech-Aktien zeigen sich im deutschen Handel schwächer. Für Evotec und Biontech geht es abwärts, Qiagen kann sich behaupten. An der Wall Street verliert... ► Artikel lesen | |
NOVAVAX | 15,736 | -0,18 % | Market Whales and Their Recent Bets on NVAX Options | ||
EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
STRYKER | 306,00 | +0,13 % | Kissigs Portfoliocheck: Ist Stryker Ron Barons neuer Favorit im Medtech-Sektor? | In meiner Kolumne "Kissigs Portfoliocheck" nehme ich regelmäßig für das "Aktien Magazin" von Traderfox die Depots der besten Investoren unserer Zeit unter die Lupe. Bei meinem 263. Portfoliocheck schaue... ► Artikel lesen | |
ILLUMINA | 111,92 | +0,88 % | Illumina-Aktie gewinnt 4,35 Prozent (111,6930 €) | Die Aktie von Illumina zählt am Donnerstag zu den großen Gewinnern an der Börse. Das Wertpapier verteuert sich heute deutlich. Ein Preisanstieg auf zwischenzeitlich 121,35 US-Dollar beschert der Illumina-Aktie... ► Artikel lesen | |
CRISPR THERAPEUTICS | 52,75 | -1,40 % | Is a Beat in the Cards for CRISPR Therapeutics (CRSP) in Q2 Earnings? | ||
AAP IMPLANTATE | 1,260 | +1,61 % | aap Implantate: EMEA-Geschäft schiebt Quartals-Umsatz an | aap Implantate hat erste Einzelheiten zur Geschäftsentwicklung im zweiten Quartal 2024 vorgelegt. Während man den detaillierten Halbjahresbericht am 14. August vorlegen will, beschränkt man sich bei... ► Artikel lesen | |
OCUGEN | 1,485 | -1,39 % | Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Novel Modifier Gene Therapy | • Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing... ► Artikel lesen | |
SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings Set to Launch First cGMP Mammalian Manufacturing Campaign | ||
INTELLIA THERAPEUTICS | 24,570 | +0,70 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
EDITAS MEDICINE | 5,322 | +2,35 % | Editas Medicine, Inc.: Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress | All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,556 | +2,96 % | EQS-News: Defence Therapeutics Inc.: Defence Therapeutics erhält Unterstützung durch das CNRI-H-Projekt von Canadian Nuclear Laboratories zur Beschleunigung der Entwicklung seines Radioimmunokonjugat-Programms | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,066 | -2,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Second Quarter 2024 Financial Results on August 5 |